These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 14663658

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Risperidone-induced hyperamylasemia, hyperlipasemia, and neuroleptic malignant syndrome: a case report.
    Ghio L, Fornaro G, Rossi P.
    J Clin Psychopharmacol; 2009 Aug; 29(4):391-2. PubMed ID: 19593182
    [No Abstract] [Full Text] [Related]

  • 43. Reversible Amisulpride-induced Elevation of Creatine Kinase (CK): A Case Series from the German AMSP Pharmacovigilance Project.
    Laoutidis ZG, Konstantinidis A, Grohmann R, Luckhaus C, Mobascher J, Cordes J.
    Pharmacopsychiatry; 2015 Jul; 48(4-5):178-81. PubMed ID: 25984709
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Risperidone-induced thrombocytopenia: a case report.
    Semba J, Okui S.
    Gen Hosp Psychiatry; 2009 Jul; 31(1):97-8. PubMed ID: 19134517
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome.
    Tsai JH, Yang P, Yen JY, Chen CC, Yang MJ.
    Pharmacotherapy; 2005 Aug; 25(8):1156-9. PubMed ID: 16207109
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Neuroleptic-induced catatonia in two hospitalized patients.
    Gugger JJ, Saad M, Smith C.
    J Pharm Pract; 2012 Apr; 25(2):250-4. PubMed ID: 22048928
    [Abstract] [Full Text] [Related]

  • 55. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H.
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
    Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD.
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
    [Abstract] [Full Text] [Related]

  • 58. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [Abstract] [Full Text] [Related]

  • 59. Neuroleptic malignant syndrome and catatonia in a patient with dementia.
    Singh D, Forlano R, Athey R.
    Aust N Z J Psychiatry; 2008 Jun; 42(6):547-8. PubMed ID: 18494081
    [No Abstract] [Full Text] [Related]

  • 60. Risperidone-induced galactorrhea associated with a prolactin elevation.
    Popli A, Gupta S, Rangwani SR.
    Ann Clin Psychiatry; 1998 Mar; 10(1):31-3. PubMed ID: 9622047
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.